NCT03208322View on ClinicalTrials.gov

Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

November 30, 2018

Primary Completion Date

February 27, 2019

Study Completion Date

February 27, 2019

Conditions
Hepatitis C
Interventions
OTHER

Non-Interventional

Non-Interventional

Trial Locations (2)

10700

Local Institution, Df

07760

Local Institution, Magdalena de las Salinas

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03208322 - Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults | Biotech Hunter | Biotech Hunter